Zoran Zdraveski Net Worth

The estimated Net Worth of Zoran Zdraveski is at least $283 Thousand dollars as of 24 December 2019. Zoran Zdraveski owns over 7,902 units of Magenta Therapeutics Inc stock worth over $89,606 and over the last 6 years he sold MGTA stock worth over $193,453. In addition, he makes $0 as Secretary and Chief Legal Officer at Magenta Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Zoran Zdraveski MGTA stock SEC Form 4 insiders trading

Zoran has made over 2 trades of the Magenta Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 7,902 units of MGTA stock worth $126,432 on 24 December 2019.

The largest trade he's ever made was selling 7,902 units of Magenta Therapeutics Inc stock on 24 December 2019 worth over $126,432. On average, Zoran trades about 2,014 units every 0 days since 2018. As of 24 December 2019 he still owns at least 128,009 units of Magenta Therapeutics Inc stock.

You can see the complete history of Zoran Zdraveski stock trades at the bottom of the page.

Zoran Zdraveski biography

Dr. Zoran Zdraveski J.D. Ph.D. serves as Secretary and Chief Legal Officer of the Company. Dr. Zdraveski has more than 19 years of experience in the legal field in the biopharmaceutical industry. Most recently he served as Vice President and Associate General Counsel at Epizyme Inc., from July 2012 to April 2017, where he established the legal team and managed all aspects of legal, intellectual property and compliance both before and after the company’s 2013 initial public offering. Prior to joining Epizyme Inc., he held patent counsel positions at Ironwood from April 2011 to July 2012 and Genzyme Therapeutics, from September 2009 to April 2011.

How old is Zoran Zdraveski?

Zoran Zdraveski is 50, he's been the Secretary and Chief Legal Officer of Magenta Therapeutics Inc since 2017. There are 9 older and 9 younger executives at Magenta Therapeutics Inc. The oldest executive at Magenta Therapeutics Inc is David Scadden, 67, who is the Independent Director.

What's Zoran Zdraveski's mailing address?

Zoran's mailing address filed with the SEC is C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.

Insiders trading at Magenta Therapeutics Inc

Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000 . The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third..., and Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.

What does Magenta Therapeutics Inc do?

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.

Complete history of Zoran Zdraveski stock trades at Magenta Therapeutics Inc

Magenta Therapeutics Inc executives and stock owners

Magenta Therapeutics Inc executives and other stock owners filed with the SEC include:

• Christina Isacson,
  Chief Business Officer
• Jason Gardner,
  President, Chief Executive Officer, Co-Founder, Director
• John Davis,
  Chief Medical Officer, Head of Research and Development
• Dr. Jason Gardner Ph.D.,
  Co-Founder, CEO, Pres & Director
• Stephen F. Mahoney J.D., MBA,
  Chief Financial & Operating Officer and Treasurer
• Anne McGeorge,
  Independent Director
• David Scadden,
  Independent Director
• Michael Bonney,
  Independent Chairman of the Board
• Alexis Borisy,
  Independent Director
• Jeffrey Albers,
  Independent Director
• Thomas Daniel,
  Independent Director
• Bruce Booth,
  Independent Director
• Blake Byers,
  Independent Director
• Amy Ronneberg,
  Independent Director
• Steve Mahoney,
  Chief Financial and Operating Officer
• Manisha Pai,
  Vice President - Communications and Investor Relations
• Zoran Zdraveski,
  Secretary and Chief Legal Officer
• Li Malmberg,
  Senior Vice President - Head of Manufacturing
• Kristen Stants,
  Chief People Officer
• Cindy Driscoll,
  Vice President - Finance
• Dr. Jan Pinkas Ph.D.,
  Sr. VP & Head of Translational Sciences
• Catherine Monaghan,
  Head of Clinical Devel. Operations
• Kristen Stants,
  Chief People Officer
• Lyndsey Scull,
  Director of Corp. Communications
• Thomas W. Beetham,
  Chief Legal Officer
• Jim Haney,
  Sr. Director of Investor Relations
• Dr. Lisa M. Olson Ph.D.,
  Head of Research & Chief Scientific Officer
• David Wayne Nichols,
  Chief Technical Officer
• Lisa Olson,
  See Remarks
• Caren Deardorf,
  Chief Commercial Officer
• Venture Fund X, L.P.Atlas V...,
  
• Rock Ventures Iv, L.P.Third...,
  
• 2016 Gp, L.L.C.Gv 2016 Gp, ...,
  
• Jason Ryan,
  See Remarks
• Venture Fund X, L.P. Atlas,
  10% owner
• Stephen F. Mahoney,
  See Remarks
• Michael P. Cooke,
  Chief Scientific Officer
• Thomas W. Beetham,
  See Remarks
• Jeffrey Humphrey,
  Chief Medical Officer
• Alison Frances Lawton,
  Director
• David Wayne Nichols,
  Chief Technical Officer
• Michael Vasconcelles,
  Director